Key Highlights
- Medline’s upcoming $50 billion IPO highlights the wealth of its founding family.
- The Mills family holds a stake worth $6 billion to $7 billion post-2021 sale.
- Combined with their earlier sale, Forbes estimates the family’s net worth at $20 billion.
- Medline’s sales and profits have grown significantly since private equity took over in 2021.
The Riches of a Medical Giant’s Founding Family
When Medline, the world’s largest medical supplies company, prepares to go public with an expected valuation of up to $55 billion this winter, it brings to light the vast fortune of its founding family. According to Forbes, the Mills family, who founded the business in 1910 and held a significant stake until 2021, now boasts a net worth estimated at $20 billion.
Family Wealth: A Legacy of Innovation
The story of Medline begins with A.L. Mills, the great-grandfather of Charlie Mills, who started by selling handmade butcher’s aprons in Chicago’s meatpacking district. He later expanded to hospital garments upon a request from a local nun, thus pioneering the medical supplies sector that would grow into a multi-billion-dollar enterprise.
Transition to Private Equity
In 2021, Medline underwent a significant transformation when the Mills family sold a majority stake in the company to private equity firms like Blackstone Group and Carlyle Group. The sale netted the family $30 billion, but they retained a substantial portion of their shares.
Current Valuation and Family Office
The most recent securities filing reveals that the Mills family’s stake is now valued between $6 billion to $7 billion based on expected share prices. When combined with the net worth from their earlier sale, Forbes estimates a total wealth of $20 billion for Charlie Mills (former CEO), Andy Mills (former president), and Jim Abrams (former COO).
Medline’s Growth Post-Private Equity
Since the transition to private equity, Medline has seen remarkable growth. Its sales reached $25.5 billion in 2024, up by 83% from its 2019 figure of $13.9 billion. Additionally, profits rebounded to $1.2 billion last year, compared with a small loss two years earlier.
Implications for the Future
The impending IPO and the estimated wealth of the founding family underscore Medline’s enduring success in the medical supplies industry. The company’s history of innovation—from the first surgeon’s gown to pioneering neonatal care products—has cemented its position as a leader, even as it transitions through ownership changes.
With the Mills family stepping back and the leadership now taken over by non-family members like current CEO Jim Boyle, Medline stands poised for continued growth in an ever-evolving healthcare landscape. The upcoming IPO will not only bring in significant capital but also provide new opportunities for stakeholders and employees alike as the company continues to innovate and expand.
Follow updates on this groundbreaking event in the business world and keep an eye on how Medline’s future unfolds under its current leadership.
